Navigation Links
Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
Date:7/22/2013

EXTON, Pa., July 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that U.S. payer trust in specific biosimilar manufacturers could dictate which companies will be most successful in the future biosimilar market.

The Biosimilars Advisory Service report entitled U.S. and EU Payer Perspectives finds that, when considering various types of potential biosimilar manufacturers, a greater proportion of surveyed U.S. payers place a high level of trust in large pharmaceutical companies with biologics and/or biosimilars experience compared with non-pharmaceutical companies or emerging market companies.  Not only are biosimilars that are developed by well-trusted companies significantly more likely to be reimbursed, but they are also more likely to encounter significantly fewer reimbursement restrictions than the branded agent.

Interviewed European payers believe that if biosimilars are produced to high quality standards and are approved by the European Medicines Agency, then generally their concerns associated with different types of manufacturer and country of production will be addressed. The majority of surveyed U.S. payers report that approval by the U.S. Food and Drug Administration (FDA) will be sufficient to allay some of their concerns about biosimilars. Looking at the data at the class level, a smaller proportion of payers say that FDA approval will address all of their concerns for biosimilar monoclonal antibodies and fusion proteins for chronic diseases, compared with biosimilar small recombinant proteins.

"Although the majority of surveyed U.S. payers believe that biosimilars and brands are very similar to one another with only minor, non-clinically significant differences, a large group believe that they are only somewhat similar with significant or possibly significant clinical differences," s
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
2. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
3. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
4. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
5. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
6. Consumer Survey Indicates Mouth Guards Worsen TMJ Symptoms As Often As Significantly Improving Them – Holistic Technologies
7. U of T engineering breakthrough promises significantly more efficient solar cells
8. SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
9. VIC Investor Network to Significantly Accelerate Technology Company Growth
10. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
11. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... May 21, 2015 Patent Offering, The ... for diagnostic or therapeutic imaging within a body lumen ... an endoscope having a low cost, single-use disposable illumination ... date was October 18, 2013 and the patent approval ... enables the physician to customize the lighting and magnification ...
(Date:5/21/2015)... , May 20, 2015 Research and Markets ... addition of the "2015 Global Survey on ... offering. The primary goal of this ... cytometry instruments and reagents. Key information the survey ... selection of flow cytometers, predominantly used applications for ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... , , ROCKAWAY, N.J., Dec. ... An Evidence-Based Approach , published by the ... for anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy ... used in the treatment of various types of cancer since ...
... , WALTHAM, Mass., Dec. 14 Decision ... pharmaceutical and healthcare issues, finds that, owing to the launches of ... than sevenfold from $790 million in 2008 to $6.1 billion in ... Kingdom and Japan. , The new Pharmacor report entitled Atrial ...
... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: DNDN ) ... offering have exercised in full their option to purchase an ... price of $24.75 per share. The exercise of the ... of 17,250,000 shares of common stock. Dendreon expects to ...
Cached Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... Applying a small mechanical force to embryonic stem ... into a specific direction of differentiation, researchers at the ... include therapeutic cloning and regenerative medicine. "Our results suggest ... inducing strong biological responses in embryonic stem cells, and ...
... A 21-year Michigan State University experiment that distills the ... natural selection at work, but could lead to ... Darwin,s seminal Origin of Species first laid out the ... professor Richard Lenski and colleagues document the process in ...
... statewide group of structural biologists with similar interests in ... on the University of Oklahoma,s Norman campus with the ... sophisticated robotics equipment. The idea for the ... facilitated a meeting among structural biologists from the OU ...
Cached Biology News:Small mechanical forces have big impact on embryonic stem cells 2Time in a bottle: Scientists watch evolution unfold 2Time in a bottle: Scientists watch evolution unfold 3